Key takeaways:
Rybelsus and Ozempic are two medications used to treat Type 2 diabetes in adults. They both contain semaglutide, but Rybelsus is a pill and Ozempic is an injection.
Rybelsus needs to be taken every day to achieve consistent levels in the body. Ozempic only needs to be injected once a week. This is due to absorption differences between oral and injectable semaglutide.
Ozempic is also approved to lower the risk of major cardiovascular events in certain people. This benefit hasn’t been confirmed with Rybelsus, but studies are ongoing. Ozempic has also been shown to provide kidney-related benefits in certain people.
Rybelsus and Ozempic aren’t approved for weight loss. But some people lose weight while taking them. Real-world studies have found comparable weight loss between the two medications.
Glucagon-like peptide-1 (GLP-1) agonists are a large and growing class of medications. Of these, Ozempic (semaglutide) is a popular injectable option for Type 2 diabetes. But did you know that Ozempic’s active ingredient is also available as an oral pill?
Rybelsus is an oral version of semaglutide for Type 2 diabetes. It works the same way in the body as Ozempic to manage blood glucose (sugar) levels. So why give yourself an injection when you can just swallow a tablet?
While Rybelsus and Ozempic have several similarities, there are a few key differences to consider. We cover four of these differences below.
Even though Rybelsus and Ozempic contain the same active ingredient, they come in different dosage forms. Rybelsus is the oral form of semaglutide, while Ozempic is the injectable form.
Rybelsus comes as an oral tablet that’s available in three doses: 3 mg, 7 mg, and 14 mg. The tablet is sensitive to moisture, heat, and light, so it should be stored in its original container.
Ozempic comes in a prefilled, multi-dose injection pen. It’s available in four doses: 0.25 mg and 0.5 mg (red pen), 1 mg (blue pen), and 2 mg (yellow pen). Unused Ozempic pens last longest in the refrigerator. After first use, an Ozempic pen can be stored in the refrigerator or at room temperature for up to 56 days.
Another difference between Rybelsus and Ozempic is dose frequency. To achieve a consistent amount of medication in the body, Rybelsus needs to be taken daily. Ozempic, on the other hand, is injected once weekly.
Semaglutide lasts a long time in the body — whether you take it by mouth or inject it. But the amount you absorb with each route is different. When it’s taken orally, you only absorb a small amount of semaglutide (less than 1%). Taking Rybelsus daily allows these small amounts to build up in your body. A larger amount of semaglutide is absorbed with the injection (over 80%), which is why Ozempic is injected once a week.
To get the most from Rybelsus, take it first thing in the morning, on an empty stomach with up to 4 oz (120 mL) of water. Wait at least 30 minutes before eating or drinking, or taking other medications.
Ozempic alternatives: Due to its popularity, semaglutide injections (Ozempic, Wegovy) are currently in shortage. If you can’t fill your prescription, here is a list of potential Ozempic alternatives your prescriber may consider.
Rybelsus for weight loss: Learn more about Rybelsus for weight loss, from potential benefits to when it might be available.
Knowing the risks: Compounded products can help people access certain medications that are in shortage. But before giving compounded semaglutide a try, it’s a good idea to understand the potential risks.
Rybelsus and Ozempic are both approved for Type 2 diabetes in adults. But Ozempic has additional proven benefits for people with both Type 2 diabetes and heart disease.
Ozempic is approved to lower the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in this group. Rybelsus is currently being studied in a longer-term trial to confirm its potential cardiovascular benefits. But until this information is available, your prescriber may determine that Ozempic is a better fit if you also have heart disease.
A recent study has also shown that Ozempic lowers the risk of major kidney disease-related events in people with chronic kidney disease (CKD) and Type 2 diabetes. This type of study hasn’t been done with Rybelsus. But it’s possible that some people taking it may see kidney-related benefits while taking it.
Ozempic isn’t currently approved for CKD in people with Type 2 diabetes. But the FDA could approve it for this use sometime in January 2025.
Neither Rybelsus nor Ozempic are approved for weight loss. But people taking them often report losing weight. One real-world study looked at Rybelsus (7 mg or 14 mg) and Ozempic (0.5 mg or 1 mg) and found similar weight loss between the medications — about 13 lbs to 14 lbs at 6 months. Ozempic is also available in a 2 mg dose. But compared to the 1 mg Ozempic dose, the difference in weight loss may not be significant.
Good to know: Semaglutide is also available in a higher-dose injection for weight loss called Wegovy. Wegovy is approved for certain adults and adolescents ages 12 and older. And higher Rybelsus doses (25 mg and 50 mg) for diabetes and weight loss may be available in the near future. The 50 mg Rybelsus dose has shown weight loss that’s comparable to Wegovy.
Yes, it’s possible to switch from Rybelsus to Ozempic (and vice versa). But this can depend on your treatment goals, health history, and dose.
According to the manufacturer, people taking the highest Rybelsus dose (14 mg) can switch to the 0.5 mg Ozempic dose. After your last Rybelsus dose, you can start Ozempic the next day. And if you’re using the 0.5 mg Ozempic dose, you can switch to the 7 mg or 14 mg Rybelsus dose. After your last Ozempic dose, you’ll wait at least 7 days before starting Rybelsus.
The manufacturer doesn’t have specific instructions for switching from Rybelsus 7 mg to Ozempic. Your prescriber can determine which Ozempic dose may be right for you.
But if you’re using the 1 mg or 2 mg Ozempic doses, you can’t switch to Rybelsus. This is because there isn’t a comparable dose. And your prescriber may have you stick with Ozempic if you also have heart disease or CKD.
Ozempic and Rybelsus are only available as brand-name medications. But GoodRx can help you navigate ways to save on your prescription.
If you’re eligible, you could pay as little as $25 for Ozempic or $10 for Rybelsus with a copay savings card. And if you’re uninsured or underinsured, you may be eligible for Ozempic or Rybelsus patient assistance programs, which offer the medication at no charge.
Semaglutide is available as a weekly injection (Ozempic) and a daily tablet (Rybelsus) for the treatment of Type 2 diabetes. Ozempic is also FDA approved to lower the risk of major cardiovascular events in certain people. And it may also be approved for chronic kidney disease in people with Type 2 diabetes in the near future.
If you don’t want to give yourself a weekly injection, Rybelsus offers an oral alternative. But it may not be an option if you’re using higher Ozempic doses (1 mg, 2 mg). You’ll also need to follow specific instructions when taking it to help you absorb as much of your dose as possible.
Talk to your healthcare team if you have questions about which option is best for you.
Granhall, C., et al. (2018). Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics.
Klobučar, S., et al. (2024). Effectiveness of oral versus injectable semaglutide in adults with type 2 diabetes: Results from a retrospective observational study in Croatia. Diabetology.
Novo Nordisk. (2020). FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus label. PR Newswire.
Novo Nordisk. (2021). Investigational 2 mg dose of Ozempic (semaglutide) injection demonstrates superior reductions in blood sugar vs Ozempic 1 mg in adults with type 2 diabetes in a phase 3 trial. PR Newswire.
Novo Nordisk. (2024). A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). ClinicalTrials.gov.
Novo Nordisk. (2024). Rybelsus semaglutide tablets [package insert].
Novo Nordisk. (2024). Ozempic (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association. PR Newswire.
Overgaard, R. V., et al. (2018). Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Therapy.
Overgaard, R. V., et al. (2021). Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clinical Pharmacokinetics.
Tuttle, K. R., et al. (2023). Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Clinical Trial.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.